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EXECUTIVE SUMMARY 
Abstract: The purpose of this study was to examine the association between a single dose of 
intraoperative dexamethasone in patients undergoing outpatient laparoscopic cholecystectomy 
surgery and postoperative pain scores and the amount of postoperative opioid administration. 
Introduction: Pain is one of the most common complaints in the postoperative period and the 
days following a patient’s procedure. While opioids are commonly used for treating 
intraoperative and postoperative pain, anesthesia providers can lessen their use by adopting 
multimodal analgesia techniques. This study attempts to fill the research gap related to the 
association of a single dose of intravenous dexamethasone intraoperatively with postoperative 
pain in patients undergoing laparoscopic cholecystectomy surgery. Dexamethasone is safe to use 
intraoperatively and when given as a single dose, has minimal side effects.  
Methodology: The design chosen for this research study was a retrospective, quantitative, case-
control design. Data collection was conducted by using patient EMR’s from CAMC. Data were 
obtained from patients ages 18-64 years who underwent outpatient laparoscopic cholecystectomy 
surgery requiring general anesthesia from June 15, 2007, to June 15, 2017. There were a total of 
200 patients selected from the 5,700 charts that met the inclusion and exclusion criteria. The 
sample consisted of a case group (N=100) of patients who received an intraoperative 4-8 mg 
single dose of dexamethasone. The control group (N=100) consisted of patients who did not 
receive dexamethasone intraoperatively. Variables of age, gender, ASA physical classification 
status, BMI, LOS, dexamethasone dose, VAS pain scores on admission and VAS pain scores on 
discharge from the PACU, and total intraoperative and postoperative opioid administration in 
morphine equivalents were collected. A p-value of < .05 was considered significant.  
Results: Comparison between the two groups showed no difference in mean age, BMI, ASA 
physical status, gender, LOS, or VAS pain scores on discharge from the PACU (p > .05). There 
was no association between the administration of dexamethasone intraoperatively and VAS pain 
scores on admission to or discharge from the PACU or total PACU opioid consumption (p > 
.05). An association was found between VAS pain scores on admission to the PACU and age (p 
= .004). An association was also found between VAS pain scores on discharge from the PACU 
and gender (p = .007) and ASA physical status (p = .041). Additionally, an association was 
found between total PACU opioid consumption and age (p = .010), female gender (p = .002), 
and ASA physical status (p = .026).   
Conclusion: The administration of a single 4-8 mg dose of dexamethasone intraoperatively was 
not associated with lower VAS pain scores upon admission or discharge from the PACU or total 
PACU opioid consumption in patients undergoing laparoscopic cholecystectomy in the 
outpatient setting.   
Implications/Recommendations: This research study did not support the association between 
the use of dexamethasone and reduced postoperative pain. Studies have proven the efficacy of 
dexamethasone and the reduction of PONV. PONV has also been shown to contribute to the 
overall discomfort of the patient in the postoperative period. For this reason, the practitioner 
should still consider using dexamethasone as part of a multimodal approach to patient 
management. Further research in the form of a randomized, prospective study should be 
implemented that could control factors such as the surgeon performing the procedure and 
anesthetic technique.    
Key Words: cholecystectomy, dexamethasone, laparoscopic, opioids, pain, postoperative 
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INTRODUCTION 
Background and Significance  
The development of minimally invasive surgery techniques has profoundly impacted the 
field of surgery. By performing a procedure laparoscopically, smaller incisions are required, less 
pain is experienced, and patients experience shorter hospital stays (Srivastava & Niranjan, 2010). 
Cholecystectomy is one of the most common reasons for hospital admission, and laparoscopic 
surgery is currently the gold standard for treatment of symptomatic gallstones or acute 
cholecystitis (Sugrue, Sahebally, Ansaloni, & Zielinski, 2015). In the United States, 
approximately 750,000 laparoscopic cholecystectomies are performed each year (Stewart, 2014). 
According to Barash et al. (2013), the pain experienced after a laparoscopic case is 
primarily visceral. That is, the pain originates from organ nociceptors. Bisgaard (2006) reviewed 
evidence related to analgesic treatment after laparoscopic cholecystectomy and recommended a 
multimodal analgesia technique consisting of Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs), cyclooxygenase-2-specific inhibitors, weak or strong opioids, and local anesthetics. 
Parenteral glucocorticoids should also be considered as they have been shown to reduce both 
postoperative pain with little evidence of complications (Bisgaard, 2006). Despite the many 
advances in pain management and the increased knowledge surrounding multimodal analgesia, 
managing pain in the postoperative period has remained a challenge for clinicians (White, 2008). 
Furthermore, disparities in pain management exist related to gender, race, and ethnicity (Cooney, 
2016; LeResche, 2011; Mossey, 2011).  
According to LeResche (2011), females tend to experience a higher rate of the pain than 
males. The cause of this difference is multifactorial and poorly understood. Mossey (2011) 
concluded that racial and ethnic minority groups receive less adequate pain treatment when 
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compared to non-Hispanic whites. Contributing factors have included underreporting of pain and 
varying cultural beliefs related to pain (Mossey, 2011). Obese patients, or those having a Body 
Mass Index (BMI) greater than 30, often present with multiple comorbidities making pain 
management challenging. The practitioner must appropriately balance the use of pharmacologic 
methods of managing pain with obesity-associated respiratory complications such as obstructive 
sleep apnea (Cooney, 2016). 
The International Association for the Study of Pain and the American Pain Society has 
used terms such as “unpleasant” and “emotional experience” when defining pain. Pain can be 
associated with actual or potential damage (Nagelhout & Plaus, 2010). Uncontrolled acute pain 
can lead to the development of chronic pain and a reduction in quality of life (Kehlet, Jensen, & 
Woolf, 2006). According to Garimella and Cellini (2013), appropriate pain management leads to 
shorter hospital stays, reduced cost, and increased patient satisfaction. Also, according to the 
authors, the focus should be placed on relieving pain, minimizing side effects, and using a 
multimodal technique. Multimodal analgesia focuses on using a variety of medications from 
different drug classes combined with nonpharmacological pain interventions. Using drugs with 
varying mechanisms of action allows the provider to mediate pain at many different levels and 
offers a personalized, patient-centered approach to pain management (Manworren, 2015). While 
opioids are commonly used for treating intraoperative and postoperative pain, lessening their use 
by employing a multimodal analgesia technique may reduce unwanted side effects (Garimella & 
Cellini, 2013). According to the authors, the patient is less likely to experience common side 
effects such as respiratory depression, nausea and vomiting, pruritus, and urinary retention.  
Dexamethasone, a glucocorticoid, reduces tissue damage and inflammation by reducing 
inflammatory mediators that amplify and maintain pain perception and by possibly inhibiting 
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phospholipase A2 (Flood, Rathmell, & Shafer, 2015). According to the authors, when used 
intraoperatively, and as a single dose, minimal side effects are experienced. Dexamethasone has 
been successfully used to reduce Post Operative Nausea and Vomiting (PONV), and some 
research shows it plays a role in reducing postoperative pain. With an elimination half-time of 
3.5-5.0 hours and duration of action of 36-54 hours, dexamethasone remains in the patient's 
systemic circulation after the surgery is completed (Flood et al., 2015). 
While its use in preventing PONV is well studied, dexamethasone’s impact on 
postoperative pain remains controversial (Hermans, Pooter, Groote, Hert, & Linden, 2012). 
Additionally, some practitioners may be hesitant to use the drug based on concerns related to 
decreased wound healing and the potential rise in blood glucose levels after dexamethasone 
administration (Murphy et al., 2014). More research has been conducted involving a condition 
called Opioid-Induced Hyperalgesia (OIH). This condition has lead to a state of hyperalgesia in 
response to chronic opioid exposure. The nociceptor becomes sensitized, and a paradoxical 
response is experienced whereby the patient becomes more sensitive to painful stimuli (Stoicea 
et al., 2015). 
OIH is among the many reasons clinicians have begun to shift towards an opioid-sparing 
anesthesia technique. Even though acute opioid exposure is unlikely to cause hyperalgesia, 
tolerance, or addiction, many patients presenting to the operating room have previously used, or 
are currently using, opioids. According to Wilkerson, Kim, Windsor, and Mareiniss (2015), there 
has been an opioid abuse epidemic in the United States. According to the authors, abuse ranges 
anywhere from heroin use to the abuse of prescribed opioids such as hydrocodone or oxycodone.  
The need to identify safe, effective, non-opioid analgesics has become increasingly 
important. Using a multimodal technique, dexamethasone may be beneficial as an adjunct pain 
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medication. The present study investigated the association between single-dose intraoperative 
dexamethasone and postoperative pain in patients undergoing outpatient laparoscopic 
cholecystectomy surgery. Studies regarding this topic have shown positive results. The 
knowledge gained from the present study could be applied to anesthesia practice at Charleston 
Area Medical Center (CAMC) in West Virginia and other facilities where outpatient 
laparoscopic cholecystectomies are performed.  
The researcher’s study focused on procedures completed in the outpatient setting. 
According to Seleem, Gerges, Shreif, Ahmed, and Ragab (2011), laparoscopic cholecystectomy 
surgery is commonly performed as day surgery or ambulatory surgery. That is, patients are 
discharged on the same day the procedure is performed. The authors concluded that laparoscopic 
cholecystectomies could be implemented as day surgeries with minimal complications and led to 
higher patient satisfaction. Common reasons for unanticipated hospital admission after day 
surgery included pain, PONV, surgical complications such as bleeding or a conversion from 
laparoscopic to an open surgical technique, and a patient’s request for admission (Lau & Brooks, 
2001).  
Literature Review 
Several randomized, controlled clinical trials have been completed examining the 
relationship between dexamethasone and postoperative pain (Bisgaard, Klarskov, Kehlet, & 
Rosenberg, 2003; Hermans et al., 2012; Lim et al., 2011; Mohtadi et al., 2014; Moyano, Garcia, 
& Caicedo, 2016; Waldron, Jones, Gan, Allen, & Habib, 2013; Yamanaga et al., 2017). While 
many have resulted in evidence supporting its use, others have found no association between the 
two. Therefore, the evidence is somewhat inconclusive and controversial. A study conducted by 
Lim et al. (2011) consisting of 120 patients between the ages of 20-65 years undergoing 
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laparoscopic cholecystectomy showed a reduction in postoperative pain with the use of 
dexamethasone. The subjects were randomly allocated to either a control group (N), a group who 
received 8 mg of dexamethasone 1-2 hours before surgery (S1) or a group who received 8 mg of 
dexamethasone intraoperatively (S2). Group N received normal saline 1 hour before induction 
and post gallbladder resection, group S1 received 8mg of dexamethasone 1 hour before induction 
and normal saline post gallbladder resection, and group S2 received normal saline 1 hour before 
induction and 8mg of dexamethasone post gallbladder resection. The scholars concluded that the 
Visual Analogue Scores (VAS) during 48 hours after the procedure of groups S1 and S2 were 
significantly lower than that of group N. The authors examined the consumption of Ketorolac 
and Tramadol postoperatively in each group. Group N consumed 51.0 ± 33.1 mg of Ketorolac 
and 16.6 ± 55 mg of Tramadol. Group S1 consumed 30.0 ± 29.1 mg of Ketorolac and 6.5 ± 17.5 
mg of Tramadol. Group S2 consumed 25.2 ± 29.1 mg of Ketorolac and 5.5 ± 19.5 mg of 
Tramadol. The investigators found that a single dose of 8 mg of intravenous dexamethasone 
given 1 hour before induction or after the start of the procedure as part of a multimodal analgesia 
regimen reduced postoperative pain (Lim et al., 2011).  
 Another double-blinded, prospective study conducted by Mohtadi et al. (2014) examining 
the impact of dexamethasone and postoperative pain in patients undergoing laparoscopic 
cholecystectomy found similar results. The study consisted of 122 patients, aged 18-60 years old 
assigned to either a case group (D) or a control group (C). The groups received a single-dose of 
intravenous dexamethasone (0.01 mg/kg, up to 8 mg) or a 2 mL injection of normal intravenous 
saline, respectively. Postoperative pain intensity was measured by VAS scores, and total 
meperidine consumption in milligrams was recorded for 24-hours postoperatively. The authors 
found a significant reduction of pain intensity in group D compared to group C after 2, 6, and 12 
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hours of surgery. At 2 hours, group C had VAS scores of 5.15 ± 2.80 and group D had VAS 
scores of 3.88 ± 1.03. At 6 hours, group C had VAS scores of 4.86 ± 2.78 and group D had VAS 
scores of 3.08 ± 1.79. At 12 hours, group C had VAS scores of 4.03 ± 1.94 and group D had 
VAS scores of 3.03 ± 1.74. However, no significant differences were noted between the two 
groups immediately after or 24 hours post surgery. The consumption of meperidine was 
significantly less in group D when compared to group C (44.26 ± 7.32 mg versus 60.24 ± 10.55 
mg).  
A randomized, double-blind clinical trial conducted by Bisgaard et al. (2003) also 
examined preoperative dexamethasone and surgical outcome after laparoscopic cholecystectomy. 
Eighty patients were randomized to receive either 8 mg of dexamethasone or a placebo 90 
minutes before the procedure. The primary endpoints for this study were fatigue and pain. The 
researchers measured C-Reactive Protein (CRP), pulmonary function, pain scores, and nausea 
and vomiting episodes preoperatively and during the first 24 postoperative hours. The results 
showed a significant reduction in postoperative CRP levels (p = .01), incisional pain during the 
first 24 postoperative hours (p < 0.05), fatigue (p = 0.01) and total requirement of opioids in the 
dexamethasone group (p < 0.05). The investigators also observed a significant reduction in pain 
scores during the first postoperative week (p < 0.05). The added total VAS scores in the first 
postoperative week were a median of 53 for the dexamethasone group and 157 for the placebo 
group. Patients in the treatment group resumed recreational activities faster (1 day versus 2 days) 
than the control group (p < 0.05).  
  Yamanaga et al. (2017) examined the effect of dexamethasone on PONV and pain in 
patients undergoing general anesthesia for laparoscopic donor nephrectomy. This retrospective 
cohort study compared donors who received a lower dose (4-6 mg) or a higher dose (8-14 mg) of 
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dexamethasone with a control group who did not receive dexamethasone. The results showed a 
28% reduction in postoperative pain and a 29% reduction in opioid consumption among the 
higher dexamethasone (8-14 mg) group. However, the results were not significant for the lower 
dexamethasone (4-6 mg) group. Total postoperative opioid consumption was 35.2 ± 29.8 mg for 
the control group, 27.8 ± 19.6 mg for the low dose group, and 25.1 ± 28.0 mg for the high dose 
group. Postoperative complications (2.7% for the control group, 4.3% for the low dose group, 
and 0% for the high dose group) and hospital length of stay (2.68 ± 0.62 for the control group, 
2.63 ± 0.59 for the low dose group, and 2.66 ± 0.62 for the high dose group) did not differ 
significantly between the groups. The researchers concluded that a single perioperative 
dexamethasone dose of 8-14 mg decreased antiemetic and narcotic requirements in the first 24 
hours after surgery. Additionally, there was no increase in surgical complications related to the 
administration of dexamethasone.  
 Karaman et al. (2013) studied the effects of dexamethasone and pheniramine hydrogen 
maleate, either alone or combined, on stress response in patients undergoing elective 
laparoscopic cholecystectomy. Eighty subjects were randomly assigned to one of four groups. A 
control group, a dexamethasone (Dekort) group (8 mg/2 mL), a pheniramine hydrogen maleate 
(Avil) group (45.5 mg/2 mL), and a combined (Dekort + Avil) group with each having 20 
patients. Authors reported that CRP levels and VAS scores were significantly lower in the 
dexamethasone group and combined group. Both the Dekort group and the Dekort + Avil group 
described a VAS score of 1 versus a VAS score of 2.5 for the control and a VAS score of 2 for 
the Avil group. Both dexamethasone and pheniramine were found to significantly reduce PONV 
(P < .001 for dexamethasone and P = .005 for pheniramine). The scholars concluded that 
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dexamethasone significantly decreased postoperative pain and systemic-acute phase response 
more so than pheniramine hydrogen maleate.    
 Oliveria, Almeida, Benzon, and McCarthy (2011) conducted a meta-analysis examining 
perioperative single dose systemic dexamethasone for postoperative pain. The effects of 
dexamethasone were evaluated by pooling studies into three groups based on dexamethasone 
dosage. The groups consisted of < 0.1 mg/kg (low group), 0.11-0.2 mg/kg (intermediate group), 
and a ≥ 0.21 mg/kg (high group). The analysis consisted of 24 randomized clinical trials with a 
combined 2,751 subjects. Results supported dexamethasone over the placebo for pain at rest and 
with movement. The intermediate and high groups showed a reduction in opioid consumption. 
The authors also found that preoperative administration of dexamethasone appeared to be more 
effective than intraoperative administration. Additionally, it was found that dexamethasone at 
doses greater than 0.1 mg/kg was an effective adjunct in a multimodal technique to reduce pain 
postoperatively.  
 Another meta-analysis conducted by Waldron et al. (2013) utilized multiple databases to 
search for randomized, controlled studies comparing pain outcomes in adult patients undergoing 
general anesthesia who were given dexamethasone versus a placebo or an antiemetic. Forty-five 
studies involving 5,796 patients were included. Dexamethasone administration doses ranged 
from 1.25-20 mg. Investigators showed that patients who received dexamethasone had lower 
pain scores at 2 hours [Mean Difference (MD) -0.49], lower pain scores at 24 hours (MD -0.48) 
and received less opioids at 2 hours (MD -0.87 mg morphine equivalents) and 24 hours (MD -
2.33 mg morphine equivalents) post surgery. Additionally, dexamethasone-treated patients 
required fewer rescue analgesics, had a longer time to rescue analgesic (MD 12.06 minutes), and 
shorter stays in the Post-Anesthesia Care Unit (PACU), (MD -5.32 minutes). The authors also 
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investigated whether dexamethasone increased the risk of adverse effects postoperatively. The 
analysis found no increase in infection or delayed wound healing, but did identify increased 
blood glucose levels at 24 hours post surgery. The scholars concluded that a single-dose of 
intravenous dexamethasone had small but significant benefits regarding postoperative analgesia.  
 In contrast, a randomized controlled trial conducted by Moyano et al. (2016) examining 
the analgesia effect of dexamethasone after arthroscopic knee surgery found that intravenous 
dexamethasone had no clinical impact on postoperative pain during the first 48 hours after the 
procedure. Seventy-eight patients were randomized to receive either 10 mg of dexamethasone 
(DM group) or 0.9% normal saline (NS group). The authors concluded that pain reduction was 
achieved through the administration of morphine and it was not a result of dexamethasone 
administration. One limitation of this study is its applicability to procedures other than 
arthroscopic knee surgery.  
Concern among clinicians exists regarding the effect of dexamethasone on the reversal of 
rocuronium using sugammadex. A prospective, single-blinded trial by Rezonja et al. (2016) 
featured 65 patients undergoing elective urological or abdominal surgery randomized to either a 
granisetron (control) or dexamethasone group (case). Neuro-Muscular Block (NMB) was 
assessed using Train-Of-Four (TOF) stimulation. The researchers concluded that the 
administration of dexamethasone did not delay the reversal of NMB when using sugammadex 
(mean of 121 ± 61 seconds for the control versus 125 ± 57 seconds for the dexamethasone 
group). Time to NMB reversal was more dependent on the ratio of train-of-four before 
sugammadex administration. However, a significant drop in plasma dexamethasone 
concentration was noted after the administration of sugammadex (810 ± 283 µg/l post 
administration versus 604 ± 208 µg/l pre-administration). The scholars concluded that 
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dexamethasone did not delay NMB reversal by sugammadex in patients who underwent general 
anesthesia.   
Statement of Problem and Research Purpose  
The purpose of this study was to examine the association between the intraoperative 
administration of dexamethasone in patients undergoing laparoscopic cholecystectomy surgery 
in the outpatient setting and postoperative outcomes including pain and opioid consumption. The 
study’s purpose was to determine if an association existed between a single dose of 
dexamethasone intraoperatively and VAS pain scores upon admission and discharge from the 
PACU and total opioid consumption in the PACU.   
METHODOLOGY 
Research Hypothesis  
The hypotheses were: 
1) Patients undergoing laparoscopic cholecystectomy surgery who received a 4-8 mg single 
dose of dexamethasone intraoperatively will have lower pain scores upon admission to 
and discharge from the PACU than patients who did not receive a single dose of 
dexamethasone intraoperatively.   
2) Patients undergoing laparoscopic cholecystectomy surgery who received a 4-8 mg single 
dose of dexamethasone intraoperatively will consume less total opioids while in the 
PACU than patients who did not receive a single dose of dexamethasone intraoperatively.  
Research Design 
This study used a retrospective, quantitative, case-control format. This design was 
appropriate because data was available from patients who have undergone laparoscopic 
cholecystectomies. The case-control design allowed for easy identification of patient 
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demographics such as age and gender and clinical characteristics that could compare patients 
who received a single dose of intraoperative dexamethasone with those who did not. A 
retrospective, case-controlled study design was employed to analyze the data to gain substantial 
research findings while adhering to limited financial and time constraints when compared with 
alternative study designs (Schulz & Grimes, 2002).  
CAMC is a not-for-profit, 956-bed academic medical center system and regional referral 
center comprised of CAMC Memorial Hospital, CAMC General Hospital, and CAMC Women 
and Children’s Hospital located in Charleston, West Virginia. Also, Teays Valley Hospital is 
located in Hurricane, West Virginia (CAMC, 2017a). CAMC General is one of only two Level I 
Trauma Centers in the state of West Virginia (CAMC, 2017b).    
A review of electronic medical records (EMR) at CAMC was conducted using patients 
requiring a laparoscopic cholecystectomy in the outpatient setting who underwent general 
anesthesia between June 15, 2007, and June 15, 2017 (McKesson Corporation, 2017). Two 
groups were developed for comparison. The case group consisted of subjects who underwent 
laparoscopic cholecystectomy surgery and received a single dose of dexamethasone 
intraoperatively. The control group consisted of subjects who experienced laparoscopic 
cholecystectomy surgery and did not receive dexamethasone intraoperatively. 
Sample Population and Description of Sample 
The sample population for this study consisted of 200 patients who underwent a 
laparoscopic cholecystectomy in the outpatient setting between June 15, 2007, and June 15, 
2017. The search yielded 5,700 randomized records that matched the inclusion and exclusion 
criteria. Patient records were filtered to show outpatient records and were randomized by 
selecting every 5th record until the predetermined sample size of 200 was met. The sample 
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consisted of a case group of 100 subjects, 18 to 64 years old who received a 4-8 mg single dose 
of dexamethasone intraoperatively. Each group consisted of 50 males and 50 females, as the 
researcher manipulated this variable. Of the 100 case subjects, 90 received 8 mg of 
dexamethasone, and 10 received 4 mg of dexamethasone. The control group consisted of 100 
subjects, 18-64 years old who did not receive dexamethasone intraoperatively. The subjects were 
identified by using the International Classification of Diseases, 9th revision, and 10th revision, 
Clinical Modification codes: 51.23 (ICD-9-CM/laparoscopic cholecystectomy) and 0FT44ZZ 
(ICD-10-CM/resection of gallbladder, percutaneous endoscopic approach).      
Inclusion Criteria: 
1. Patients 18 to 64 years of age. 
2. American Society of Anesthesiologists (ASA) physical status classification I-III. 
3. Patients who underwent outpatient laparoscopic cholecystectomy under general 
anesthesia and did or did not receive a 4-8 mg single-dose of dexamethasone 
intraoperatively.  
Exclusion Criteria: 
1. Patients less than 18 years of age or older than 64 years of age. 
2. Patients with an ASA physical status greater than III.  
3. Laparoscopic cholecystectomy converted to open cholecystectomy.  
4. Patients whose home medications included opioids or analgesics for treatment of chronic 
pain.  
5. Patient whose home medications included glucocorticoids.  
6. Patients who received dexamethasone in the preoperative period or PACU on the day of 
surgery.  
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7. Patients with a documented history of drug or alcohol abuse.  
Procedures and Protocol 
A retrospective chart review was conducted using the EMR databases at CAMC for 
patients who underwent outpatient laparoscopic cholecystectomy surgery requiring general 
anesthesia between June 15, 2007, and June 15, 2017.  The patients who met the inclusion 
criteria were selected for this study. Patient demographics and clinical variables collected from 
the records included age, gender, ASA physical classification status, height, weight, BMI, 
Length Of Surgery (LOS), dexamethasone dosage or not, intraoperative opioid administration, 
postoperative opioid consumption, and pain scores upon admission and discharge from the 
PACU.  
 Age was measured in years at the time of arrival to the hospital. Gender was classified as 
male or female. ASA physical classification status is a subjective measurement based on overall 
health that is assigned to the patient by the anesthesia provider conducting the preoperative 
anesthesia assessment. There are six ASA physical status classifications: (I) normal, healthy 
patient, (II) patient with mild systemic disease, (III) patient with severe systemic disease, (IV) 
patient with severe systemic disease that is a threat to life, (V) patient is not expected to live 
without surgery, and (VI) patient is brain-dead and is donating organs (ASA, 2017). BMI was 
collected from the preoperative anesthesia evaluation or calculated using the patient’s height in 
meters and weight in kilograms following CDC guidelines (Centers for Disease Control and 
Prevention, 2017). LOS was recorded in minutes. Total intraoperative and PACU opioid 
consumption data was collected and converted to morphine equivalents in milligrams using an 
opioid conversion calculator, allowing for comparison among different opioids (ClinCal, 2017). 
Dexamethasone administration was measured in milligrams. Pain assessments, a subjective 
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measurement, were recorded using a numeric rating scale of 0-10. A score of “0” indicated no 
pain and a score of “10” indicated the worst pain imaginable (Breivik et al., 2008).  
 The final anesthesia record was used to identify the primary independent variable, the use 
or not of dexamethasone and other independent variables. Patient records were also reviewed to 
determine the dependent variables: total amount of opioid consumption and pain scores in the 
PACU upon admission and discharge. The researcher examined the anesthesia records, 
preoperative evaluation records, medication administration records, and PACU records for 
specific data. The data was organized using Microsoft Excel. Each selected patient was assigned 
a study number. This number allowed patient identifiers to remain private and confidential 
(Appendix A). Patient demographic data such as age, gender, height, weight, BMI, length of 
surgery, ASA physical status, dexamethasone administration, total opioid consumption 
intraoperatively, and pain scores and opioid consumption in the PACU was organized using an 
Excel spreadsheet (Appendix B).   
Statistical Design and Analysis  
The purpose of this research was to examine the association between single-dose 
intraoperative dexamethasone and postoperative pain in patients undergoing laparoscopic 
cholecystectomy surgery. The dependent variables included the consumption of opioids in the 
PACU, pain scores on admission to the PACU, and pain scores at discharge from the PACU. The 
independent variables were the administration of IV dexamethasone and dosage, age, gender, 
BMI, LOS and ASA physical status classification. Chi-squared test was used to determine if 
there was a statistically significant difference related to gender and ASA classification between 
the two groups. Independent t-tests were used to compare the mean difference of age, BMI, LOS, 
VAS pain scores on admission and discharge from the PACU, and total intraoperative and total 
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opioid consumption in the PACU between the two groups. A p-value of < .05 was statistically 
significant for this research study. Statistical analysis used SPSS software (SPSS IBM Company, 
2017).  
Ethical Considerations 
The CAMC and West Virginia University-Charleston Division Institutional Review 
Board approved this study on July 20, 2017 (Appendix C).  
RESULTS 
Presentation, Analysis, and Interpretation of Data  
 The study sample consisted of 200 patients between 18-64 years old within the CAMC 
medical system who underwent outpatient laparoscopic cholecystectomy surgery.  The patients 
were divided into two groups based on whether dexamethasone was administered 
intraoperatively. The case group (n=100) included patients who received intraoperative 
dexamethasone, and the control group (n=100) consisted of patients who did not receive 
dexamethasone. A comparison between the two groups means difference using independent t-
tests showed no statistical difference in age, BMI, ASA physical status, gender, or LOS, (Table 
1). The mean age for the case group was 43.6 ± 13.9 years versus a mean of 44.6 ± 12.6 years for 
the control group, and the mean difference was not statistically significant (p > .05). The mean 
BMI for the case and control groups was 33.6 ± 8 kg/m2 and 31.8 ± 6.9 kg/m2, respectively, and 
the mean difference was not statistically significant (p >.05). Each study group consisted of 50 
males and 50 females. The majority of all subjects (N=187) were classified as an ASA physical 
status classification of II or III. The mean LOS for the case group was 53.5 ± 21.6 minutes and 
51.9 ± 21.8 minutes for the control group (p > .05).  A p-value of < .05 was considered 
significant.  
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Table 1: Demographic and Clinical Characteristics of the use of Dexamethasone in Patients Who 
Underwent Laparoscopic Cholecystectomy Surgery. 
 
 
 
Variable 
Total Sample Study Groups Statistical Value 
 
Total 
N=100 
Mean (SD) 
Did not receive 
dexamethasone 
N=100 (50%) 
Mean (SD) 
Received 
dexamethasone 
N=100 (50%) 
Mean  (SD) 
 
p-Value 
 
Age (years) 
 
44.1 (13.2) 
44.6 (12.6) 43.6 (13.9) (NS) 
BMI (kg/m2) 
 
32.7 (7.5) 31.8 (6.9) 33.6 (8) (NS) 
Gender (F/M) 
 
F = 100 
 
M = 100 
 
F = 50 
 
M = 50 
 
F = 50 
 
M = 50 
(NS) 
ASA I N (%) 
 
ASA II N (%) 
 
ASA III N (%) 
 
13 (6.5%) 
 
105 (52.5%) 
 
82 (41%) 
7 (7%) 
 
47 (47%) 
 
46 (46%)  
6 (6%) 
 
58 (58%) 
 
36 (36%) 
(NS) 
LOS (minutes) 
 
52.7 (21.7) 51.9 (21.8) 53.5 (21.6) (NS) 
Dexamethasone 
Dose (mg) 
 
0 
4 
8 
 
Frequency 
 
100 
 
10 
 
90 
 
Frequency 
 
100 
 
0 
 
0 
 
 
Frequency 
 
0 
 
10 
 
90 
 
(NS) 
NS=Not Significant (p > .05), SD=Standard Deviation, BMI=Body Mass Index, ASA=American 
Society of Anesthesiologists physical status classification, LOS=Length of surgery, M=male, 
F=female, Dose=milligrams.  
 
 A comparison of the two groups showed a statistically significant difference in mean 
difference of VAS pain scores on admission to the PACU, total intraoperative opioid 
administration, and overall PACU opioid administration. Upon admission to the PACU, patients 
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who received dexamethasone presented a mean pain score of 2.7 ± 3.5 versus 3.9 ± 3.6 for those 
who did not receive dexamethasone (p < .05). There was no statistically significant mean 
difference in VAS pain scores upon discharge from the PACU between the two groups (p > .05), 
(Table 2). Upon discharge from the PACU, patients who received dexamethasone presented a 
mean pain score of 2.4 ± 1.8 versus 2.8 ± 1.2 for those who did not receive dexamethasone (p > 
.05).  Those who received dexamethasone received a mean of 24.9 ± 10.3 morphine equivalents 
intraoperatively and the group who did not receive a mean of 28.6 ± 11.6 morphine equivalents. 
This finding was statistically significant (p < .05). Total PACU opioid consumption was 
statistically significant with a mean difference of 5.6 ± 5.7 morphine equivalents for patients who 
received dexamethasone intraoperatively and 8 ± 7.2 morphine equivalents for patients who did 
not receive dexamethasone (p < .05), (Table 2).  
Table 2:  Comparison of Intraoperative and PACU Opioid Administration and VAS Pain Scores 
on PACU Admission and Discharge.  
 
 
 
Variable 
Total Sample Study Groups Statistical Value 
 
Total Sample 
N=100 
Mean (SD) 
Did not receive 
dexamethasone 
N=100 (50%) 
Mean (SD) 
Received 
dexamethasone 
N=100 (50%) 
Mean  (SD) 
 
p-Value 
 
VAS – PACU 
admission 
(0-10) 
 
3.3 (3.6) 3.9 (3.6) 2.7 (3.5) .018* 
VAS – PACU 
discharge 
(0-10) 
 
2.6 (2) 2.8 (2.2) 2.4 (1.8) (NS) 
Intraoperative 
opioid 
administration 
(morphine 
equivalents) 
 
 
 
26.8 (11.1) 
28.6 (11.6)  24.9 (10.3) .018* 
PACU opioid 
administration 
(morphine 
equivalents) 
 
 
6.9 (6.6) 
8 (7.2) 5.6 (5.7) .013* 
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*Indicated significant value (p < .05), NS= Not Significant (p > .05), SD=Standard Deviation, 
VAS = Verbal Analogue Scale pain score, PACU = post-anesthesia care unit.  
 
 A linear regression analysis was conducted to evaluate the association of VAS pain 
scores on admission to the PACU with age, gender, BMI, ASA, dexamethasone administration 
or not, and dexamethasone dosage. The researcher found a statistically significant association 
between VAS pain scores on admission to the PACU and age (p = .004), (Table 3).    
Table 3: Linear Regression Analysis Between VAS Pain Scores on Admission to the PACU 
and Dexamethasone Use in Patients Undergoing Laparoscopic Cholecystectomy 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 6.105 1.537  3.971 .0001 
Age -.063 .022 -.231 -2.892 .004* 
Gender: F=1, M=0  .467 .524 .065 .891 .374 
BMI -.048 .036 -.100 -1.343 .181 
ASA .790 .512 .131 1.542 .125 
DEX: Y=1, N=0 -2.413 2.304 -.336 -1.047 .296 
Dose .171 .297 .186 .577 .565 
Dependent Variable: VAS pain scores on PACU admission. *Indicates Statistical Significance at 
p < .05, Gender (M=male, F=female), BMI=Body Mass Index, ASA=American Society of 
Anesthesiologists physical status classification, DEX (Y=yes, N=no), Dose=milligrams.  
 
 A linear regression analysis was conducted to evaluate the association between VAS pain 
scores on discharge from the PACU with age, gender, BMI, ASA, dexamethasone administration 
or not, and dexamethasone dosage. The results indicated a statistically significant association 
between VAS pain scores on discharge from the PACU and gender (p = .007) and ASA physical 
status (p = .041), (Table 4).  
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Table 4: Linear Regression Analysis Between VAS Pain Scores on Discharge from the PACU 
and Dexamethasone Use in Patients Undergoing Laparoscopic Cholecystectomy 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 1.128 .881  1.281 .202 
Age -.003 .012 -.019 -.236 .814 
Gender: F=1, M=0 .825 .300 .203 2.751 .007* 
BMI -.003 .020 -.010 -.137 .891 
ASA .603 .294 .177 2.052 .041* 
DEX: Y=1, N=0 -.834 1.320 -.205 -.632 .528 
Dose .067 .170 .128 .395 .693 
Dependent Variable: VAS pain scores on PACU discharge. *Indicates Statistical Significance at 
p < .05, Gender (M=male, F=female), BMI=Body Mass Index, ASA=American Society of 
Anesthesiologists physical status classification, DEX (Y=yes, N=no), Dose=milligrams. 
  
A linear regression analysis was conducted to evaluate the association between total 
opioid consumption in the PACU and age, gender, BMI, ASA physical status, dexamethasone 
administration or not, and dexamethasone dosage. The results indicated a statistically significant 
association between total opioid consumption in the PACU and age (p = .010), gender (p = .002), 
and ASA physical status (p = .026), (Table 5).    
Table 5: Linear Regression Analysis Between PACU Opioid Consumption and Dexamethasone 
Use in Patients Undergoing Laparoscopic Cholecystectomy 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 6.605 2.746  2.405 .017 
Age -.101 .039 -.204 -2.608 .010* 
Gender: F=1, M=0 2.905 .936 .222 3.105 .002* 
BMI -.012 .064 -.014 -.195 .846 
ASA 2.052 .915 .187 2.241 .026* 
DEX: Y=1, N=0 -5.284 4.116 -.403 -1.284 .201 
Dose .407 .530 .242 .768 .444 
Dependent Variable: Total PACU Opioid Consumption in Morphine Equivalents. *Indicates 
Statistical Significance at p < .05, Gender (M=male, F=female), BMI=Body Mass Index, 
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ASA=American Society of Anesthesiologists physical status classification, DEX (Y=yes, N=no), 
Dose=milligrams.  
 
 An independent t-test analysis compared gender to VAS pain score on admission, VAS 
pain score on discharge from the PACU, total intraoperative opioid administration, and total 
opioid consumption in the PACU. The analysis showed a statistically significant association 
between gender and VAS pain score on discharge from the PACU (p = .026) and total PACU 
opioid consumption (p = .003), (Table 6).  
Table 6: Independent T-Test Comparing Gender and VAS Pain Score on Admission, VAS Pain 
Score on Discharge, Total Intraoperative Opioids, and Total PACU Opioids in Patients 
Undergoing Laparoscopic Cholecystectomy  
 
t-test for Equality of Means 
df Sig. (2-tailed) 
Mean 
Difference 
VAS Score: Admission Equal variances assumed 198 .277 -.5550 
Equal variances not 
assumed 
197.550 .277 -.5550 
VAS Score: Discharge Equal variances assumed 198 .026* -.640 
Equal variances not 
assumed 
184.920 .026* -.640 
Total Intraoperative 
Opioids 
Equal variances assumed 198 .801 -.39670 
Equal variances not 
assumed 
193.458 .801 -.39670 
Total PACU Opioids Equal variances assumed 198 .003* -2.76400 
Equal variances not 
assumed 
183.043 .003* -2.76400 
*Indicates statistical significance at p < .05. VAS=Verbal Analogue Scale, PACU=post- 
anesthesia care unit.  
 
Further analysis was conducted to assess whether the statistical significance applied to 
males or females. Using ANOVA, group difference means indicated that females had a mean 
VAS pain score on discharge from the PACU of 2.89 and males had a mean VAS pain score of 
2.25. Females consumed a mean of 8.28 morphine equivalents in the PACU and males consumed 
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a mean of 5.52 morphine equivalents. These findings were statistically significant (p < .05), 
(Table 7).       
Table 7: Gender and VAS Pain Score on Admission, VAS Pain Score on Discharge, Total 
Intraoperative Opioids, and Total PACU opioids in Patients Undergoing Laparoscopic 
Cholecystectomy 
 
Gender: F = 1, M = 
0 N Mean 
Std. 
Deviation 
VAS Score: 
Admission 
0 100 3.015 3.5108 
1 100 3.570 3.6825 
VAS Score: 
Discharge* 
0 100 2.25 1.731 
1 100 2.89 2.274 
Total Intraoperative 
Opioids 
0 100 26.5745 10.24703 
1 100 26.9712 11.95831 
Total PACU 
Opioids* 
0 100 5.5185 5.43688 
1 100 8.2825 7.29542 
*Indicates statistical significance at p < .05. Gender (M=male, F=female), VAS=Verbal 
Analogue Scale, PACU=post-anesthesia care unit.  
 
 
DISCUSSION 
Discussion of Study Results   
 The purpose of the present study was to determine the association between a single dose 
of intraoperative dexamethasone and postoperative pain. The hypotheses predicted patients 
undergoing laparoscopic cholecystectomy surgery who received a single 4-8 mg dose of 
dexamethasone intraoperatively would have lower VAS pain scores upon admission and 
discharge from the PACU. Additionally, these patients would have consumed less total opioids 
in the PACU. The researcher wanted to make the case and control groups as similar as possible 
and therefore, purposefully chose 50 males and 50 females for each group.   
The results of Chi-square and independent t-tests showed there were not statistically 
significant differences in mean age, BMI, gender, ASA physical status, or LOS between the case 
and control groups. T-tests comparing the two groups revealed a statistical significance between 
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dexamethasone administration and VAS pain scores upon admission to the PACU and total 
PACU opioid consumption. When dependent variables were included in a linear regression 
analysis, no statistically significant association was found between the administration of a single 
4-8 mg dose of dexamethasone and VAS pain scores upon admission or discharge from the 
PACU or total PACU opioid consumption.    
 When factoring in age, gender, BMI, ASA physical status, dexamethasone 
administration or not, and dexamethasone dose, there was not a statistically significant 
association between dexamethasone administration and mean difference VAS pain score on 
admission to the PACU, VAS pain score on discharge from the PACU, or total opioid 
consumption in the PACU. These results are more applicable to the clinical setting; as patient 
characteristics must be taken into account when determining if an association exists between a 
pharmacological drug and a patient population. Analysis showed an association between age and 
VAS pain scores on admission to the PACU.  There was also an association between gender and 
ASA physical status and VAS pain scores on discharge from the PACU. Additionally, there was 
an association between age, gender, and ASA physical status and total PACU opioid 
consumption. 
Further analysis was conducted to examine the association between age categories and 
VAS pain score on admission to the PACU. Patients were assigned to either group 1 (18-35 
years old), group 2 (36-50 years old), or group 3 (51-64 years old). An ANOVA showed a 
statistically significant difference in the mean VAS pain score on admission for group 3 
compared to group 1 (p = .046). However, there was not a statistically significant difference in 
mean VAS pain score on PACU admission when comparing group 3 to group 2 (p > .05). Group 
1 had a mean difference VAS pain score of 2.6 ± 2.9, group 2 had a mean difference VAS pain 
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score of 3.5 ± 3.7, and group 3 had a mean difference VAS pain score of 3.1 ± 3.5 (Data not 
shown). Additional analysis showed that compared to group 1, group 3 received statistically 
significantly less intraoperative opioids (p = .024), (24.4 ± 9.3 morphine equivalents versus 29.5 
± 11.9 equivalents), (Data not shown.) This is a possible explanation as to why group 3 had 
higher VAS pain scores upon admission to the PACU.  
The results showed an association between female gender and higher VAS pain scores on 
discharge from the PACU. This is consistent with findings from a review by Lombana and Vidal 
(2012). The authors found that for various reasons including physiological, neural, hormonal, 
psychological, social, and cultural factors women tend to report pain more frequently and also 
have a lower threshold for pain when compared to men. Additionally, the authors concluded that 
women describe more postoperative effects such as PONV and headaches. Further analysis was 
conducted to examine the association between ASA physical status and VAS pain score on 
discharge from the PACU. Patients with an ASA 3 physical status had a mean pain score of 2.8 ± 
1.9, which was statistically significantly higher than the means for patients with an ASA 2 
physical status (2.6 ± 2.2) and patients with an ASA 1 physical status (1.5 ± 1.7), (Data not 
shown). A patient with an ASA physical status of 3 is classified as having severe systemic 
disease. The increase in comorbidity could be associated with increased postoperative pain. 
However, research needs to be conducted to see if an association exists between increasing ASA 
physical status and postoperative pain.   
Linear regression analysis showed that females consumed significantly more opioids in 
the PACU. This is consistent with the findings from Lombana and Vidal (2012). Additionally, 
age and ASA status were found to have a statistically significant association with total opioid 
consumption in the PACU. Additional analysis was performed to determine the association. 
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Patients were once again assigned to group 1 (18-35 years old), group 2 (36-50 years old), or 
group 3 (51-64 years old) and an ANOVA was performed. The results showed no statistically 
significant difference in mean opioid consumption in the PACU between the three groups (p > 
.05), (Data not shown). However, when examining the association between ASA and total opioid 
consumption in the PACU, the researcher found that patients with an ASA 3 physical status 
consumed significantly more opioids compared to patients with an ASA 1 and ASA 2 physical 
status. Again, this association could be related to an increase in patient comorbidity and the fact 
that fewer opioids were given intraoperatively for group 3. A large-scale, randomized 
prospective study is needed to show whether increasing ASA physical status is related to 
increased pain and opioid consumption in the postoperative period.   
The present study showed no association between the administration of a single dose of 
dexamethasone and VAS pain score upon admission and discharge from the PACU or total 
PACU opioid consumption. Therefore, the researcher’s hypotheses were rejected. Several studies 
have shown a reduction in postoperative pain and PACU opioid administration when 
dexamethasone was given intraoperatively (Bisgaard et al., 2003; Lim et al., 2011; Mohtadi et 
al., 2014; Waldron et al., 2013). However, other studies have shown no association (Moyano et 
al., 2016). This could be explained by the study's small sample size, the inclusion of only one 
hospital network, and the retrospective study design.  
Study Limitations 
 There were multiple limitations to this study. The study used a retrospective, case-control 
design, which limits the findings to an “association” only. A prospective study where the 
researcher can have more control and technique is consistent is needed to prove causation. There 
was not a standard anesthetic or surgical technique for each case. All patients involved in this 
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study were from hospitals within the CAMC network and may not represent the overall 
population. While current opioid use and drug or alcohol abuse were included in the exclusion 
criteria, patients may have failed to reveal this information to the provider. To assess pain, the 
VAS pain score was used. However, pain has been subjective and varies between individuals. An 
objective measurement of pain is not available.   
 The participants in the study were administered different doses of dexamethasone at 
different times. Additionally, only intraoperative and postoperative opioids were included in the 
study. Other medications that could not be transferred to morphine equivalents such as Non-
Steroidal Anti-Inflammatory Drugs (NSAIDs), local anesthetics, and intravenous acetaminophen 
could have impacted postoperative pain scores and opioid consumption. Finally, a lack of 
documentation by nurses, anesthesia providers, and the researcher could have affected the 
results.   
IMPLICATIONS AND RECOMMENDATIONS 
 This study provides clinical evidence to practitioners and researchers about the use of 
dexamethasone in patients undergoing laparoscopic cholecystectomy in the outpatient setting. A 
review of the literature recommends the use of a multimodal analgesia technique for managing 
postoperative pain. This research study did not support the association between the use of 
dexamethasone and reduced postoperative pain. Studies have proven the efficacy of 
dexamethasone and the reduction of PONV. PONV has also been shown to contribute to the 
overall discomfort of the patient in the postoperative period. For this reason, the practitioner 
should still consider using dexamethasone as part of a multimodal approach to patient 
management. Further research in the form of a randomized, prospective study should be 
implemented that could control factors such as the surgeon performing the procedure, anesthetic 
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technique, the administration of NSAIDs, local anesthetics, and intravenous acetaminophen, and 
other limitations that the present study was unable to control.   
CONCLUSION 
 In this study, the administration of a single 4-8 mg dose of dexamethasone 
intraoperatively was not associated with lower VAS pain score upon admission or discharge 
from the PACU or total PACU opioid consumption in patients undergoing laparoscopic 
cholecystectomy in the outpatient setting.  
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APPENDICES 
Appendix A: Collection Tool 1 
Patient Study Number Patient Identification Number 
1  
2  
3  
4  
5  
…  
200  
 
Appendix B: Data Collection Tool 2 
Patient 
# 
Age 
(year
s) 
ASA  
(I-III) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kg/m2) 
Dexamet
hasone 
(Y=1, 
N=0) 
Gender 
(F=1, 
M=0) 
Dose 
(mg) 
Pain 
Score 
Admissi
on 
(0-10) 
Pain 
Score   
Discharge 
(0-10) 
LOS 
– 
(min
) 
Total 
Intraop 
Opioids 
(morphine 
equiv.) 
Total PACU 
Opioids 
(morphine 
equiv.) 
1              
2              
3              
4              
5              
…              
200              
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